Scarica l'app Stockscreener
2.35
3.69%
-0.09
Editas Medicine Inc Borsa (EDIT) Ultime notizie
EDIT Set to Begin First-in-Human Study in Hypercholesterolemia - Zacks Investment Research
Editas Medicine (NasdaqGS:EDIT) Stock Forecast & Analyst Predictions - Simply Wall Street
Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy - Yahoo Finance
Opaleye Management Inc. Buys 1,934,933 Shares of Editas Medicine, Inc. $EDIT - MarketBeat
EDIT: EDIT-401 targets up to 90% LDL reduction, with first patient dosing on track for this year - TradingView
Editas Medicine at Cantor conference: in vivo CRISPR push advances - Investing.com
Editas Medicine (NASDAQ: EDIT) Grants 950,000 Derivative Securities to CMO Ory Daniel Scott on September 8, 2026 - Kalkine Media
Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Editas Medicine (NASDAQ: EDIT) awards options vesting through 2030 to its CMO - Stock Titan
Editas Medicine (NASDAQ: EDIT) CMO named as reporting insider - Stock Titan
Editas Medicine grants stock options to new chief medical officer - investing.com
Editas Medicine grants stock options to new chief medical officer By Investing.com - Investing.com Australia
Editas Medicine grants stock options to new chief medical officer By Investing.com - Investing.com Nigeria
Editas Medicine grants stock options to new chief medical officer By Investing.com - Investing.com Canada
Editas Medicine grants stock options to new chief medical officer By Investing.com - Investing.com India
Editas Medicine grants stock options to new chief medical officer By Investing.com - Investing.com UK
New medical chief can earn the right to buy 950,000 Editas shares - Stock Titan
Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401 - MarketBeat
Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401 - Yahoo Finance
Editas Medicine, Inc. SEC Filing (Sep 9, 2026) - Stock Titan
Editas Medicine Reports Inducement Grants to New Chief Medical Officer - GlobeNewswire
Editas Medicine Reports Inducement Grants to New Chief Medical Officer - Yahoo Finance
Editas Medicine names Dan Ory as chief medical officer By Investing.com - Investing.com South Africa
EDIT: EDIT-401 aims for unprecedented LDL reduction, with first human data expected in 2027 - TradingView
Editas Medicine at Wells Fargo conference: a focused bet on CRISPR By Investing.com - Investing.com India
Editas Medicine at Wells Fargo conference: a focused bet on CRISPR - Investing.com
Editas Medicine at Wells Fargo conference: a focused bet on CRISPR - Investing.com UK
Editas Medicine CFO Parison Amy Retains 13,839 Shares After Selling 453 at $3.04 Each - Kalkine Media
Editas Medicine Appoints Dan Ory as Chief Medical Officer - citybiz
Editas Medicine names Dan Ory as chief medical officer By Investing.com - Investing.com Nigeria
Editas Medicine names Dan Ory as chief medical officer By Investing.com - Investing.com Canada
A potential gene-editing treatment moves toward trials as Editas adds a veteran with more than 25 years' experience. - Stock Titan
Editas Medicine names Dan Ory as chief medical officer - Investing.com
Editas Medicine names Dan Ory as chief medical officer By Investing.com - Investing.com UK
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer - GlobeNewswire Inc.
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer - The National Law Review
Seven Fleet Capital Management LP Takes Position in Editas Medicine, Inc. $EDIT - MarketBeat
Editas Medicine CSO Linda Burkly Sells 709 Shares to Cover RSU Tax Withholding - Kalkine Media
Editas Medicine (NASDAQ:EDIT) CEO Gilmore Neil O'neill Sells 5,124 Shares of Stock - MarketBeat
Editas Medicine CFO Amy Parison Sells Shares in September 2026 Under Pre-Set Plan - kalkinemedia.com
Editas Medicine CEO Gilmore Neil O'Neill Sells 5,124 Shares to Cover Tax Withholding on RSU Vesting - kalkinemedia.com
Editas Medicine (EDIT) CSO stock sale follows tax plan - Stock Titan
Pre-set plan triggers Editas (NASDAQ: EDIT) CFO share sale - Stock Titan
Editas Medicine (NASDAQ: EDIT) CEO sells 5,124 shares in tax-plan trade - Stock Titan
Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Editas Medicine (EDIT) Slides 1.3% to $3.04 as Support Level Comes into FocusRetracement Entry - vinanet.vn
Editas Medicine (EDIT) Slides 1.3% to $3.04 as Support Level Comes into FocusGamma Squeeze - siam.in
EditasSlow Progress Doesn't Mean No Progress For In-Vivo Gene Editor (NASDAQ:EDIT) - Seeking Alpha
BlackRock Inc. Takes Position in Editas Medicine, Inc. $EDIT - MarketBeat
Boston and New York will host Editas Medicine talks this month - stocktitan.net
4.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):